Previous 10 | Next 10 |
home / stock / wxxwy / wxxwy news
2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...
2024-02-08 07:41:00 ET Summary WuXi AppTec, which could be banned from doing business with federal agencies under proposed legislation, derived 65% of its revenue from the U.S. in the first half of last year. The provider of outsourced services to drug makers said it has never spo...
2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...
2024-02-01 03:00:00 ET Summary Beijing is rolling out a host of measures to boost economic growth and support sagging stock markets. The policies helped Hong Kong’s Hang Seng jump 4.2% last week, breaking a January losing streak. Under a new policy, market valuation will be...
2024-01-18 00:00:00 ET Summary Emerging markets equities saw positive performance in 4Q 2023, driven by valuation re-rating and currency strength. Taiwan Region, India and South Korea boosted benchmark returns, while China underperformed. Brazil remains the Strategy’s l...
2024-01-08 06:37:00 ET More on Wuxi Biologics ADR WuXi Bio Prescribes Share Buyback To Relieve Revenue Pain WuXi Biologics: Holiday Fire Sale For Leading CRDMO Historical earnings data for Wuxi Biologics ADR Financial information for Wuxi Biologics ADR ...
2023-12-13 20:30:00 ET Summary After its shares plunged more than 30% in a week, WuXi Bio announced a buyback of 10% of its shares, saying the battered price did not reflect the company’s value or business prospects. The company blamed the weaker revenue outlook on a financ...
2023-12-10 02:15:00 ET Summary Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib to Germany's Merck in a $605 million deal. Xtalpi, a China-US AI drug discovery company, has filed for a Hong Kong IPO after raising $780 million in venture...
2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...
2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc ADR Company Name:
WXXWY Stock Symbol:
OTCMKTS Market:
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year PR Newswire SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), anno...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...
WuXi Biologics Receives AAA MSCI ESG Rating PR Newswire SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating ...